J&J's Gamma First PMA Submission For Vascular Brachytherapy System
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's premarket approval application for the Gamma brachytherapy system for treatment of coronary artery disease has been granted expedited review by FDA and potentially could be approved by year-end or early 2000, the company indicated following its announcement July 14 of the PMA filing.
You may also be interested in...
Gamma System Late Thrombosis Concern Mitigated By Outside Data - Cordis
Johnson & Johnson Cordis is hoping for a chance to make its case before FDA's Circulatory System Devices Panel that FDA should consider data neither generated by the company nor included in the premarket approval application for its Gamma brachytherapy system for treatment of coronary artery restenosis.
Gamma System Late Thrombosis Concern Mitigated By Outside Data - Cordis
Johnson & Johnson Cordis is hoping for a chance to make its case before FDA's Circulatory System Devices Panel that FDA should consider data neither generated by the company nor included in the premarket approval application for its Gamma brachytherapy system for treatment of coronary artery restenosis.
J&J's Gamma Brachytherapy System Effectively Reduces Restenosis - TCT
Physicians treating in-stent restenosis with intravascular brachytherapy should avoid placing new stents at the time of radiation, Paul Teirstein, MD, Scripps Clinic, La Jolla, California cautioned in a Sept. 23 release announcing the results of the Johnson & Johnson GAMMA I trial.